Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

NCT04336241 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT04336241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04336241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
Lead sponsor
Replimune, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 17, 2019
Completion date
October 31, 2026
Enrollment
36 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer